Table 1.
Diagnosis and sociodemographic features at the beginning of first-line biologics treatment by time periods.
| Variable | 2007–2009 | 2010–2013 | 2014–2017 | 2018–2020 | p | Total |
|---|---|---|---|---|---|---|
| Number of participating centers* | 14 | 13 | 27 | 31 | 38 | |
| Number of patients included | 1522 | 786 | 886 | 1349 | 4543 | |
| Diagnosis, n (%) | < 0.001 | |||||
| RA | 870 (57.2) | 390 (49.6) | 328 (37.0) | 605 (44.8) | 2193 (48.3) | |
| PsA | 318 (20.9) | 194 (24.7) | 280 (31.6) | 414 (30.7) | 1206 (26.6) | |
| AS | 334 (21.9) | 202 (25.7) | 278 (31.4) | 330 (24.5) | 1144 (25.2) | |
| Demographic characteristics | ||||||
| Female gender, n (%) | 933 (61.3) | 462 (58.8) | 456 (51.5) | 809 (60.0) | 0.104 | 2660 (58.6) |
| Age at the beginning of first biologic, mean ± SD | 51.0 ± 14.2 | 50.9 ± 14.0 | 50.5 ± 13.3 | 52.1 ± 13.2 | 0.075 | 51.2 ± 13.7 |
*Centers that included at least one patient in this analysis.